Cash · 2019–2025
Monte Rosa Therapeutics cash
$130M−42.1% · FY2025
Monte Rosa Therapeutics (GLUE) reported $130M in cash for fiscal 2025, −42.1% year on year.
Cash — Cash and cash equivalents is money available immediately at the balance-sheet date. It excludes short-term investments, which many large companies hold far more of.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2019–2025 compound annual growth +55.3%
Cash at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Monte Rosa Therapeutics cash |url=https://companiesranked.com/en/company/monte-rosa-therapeutics/cash-on-hand |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Monte Rosa Therapeutics cash. CompaniesRanked. https://companiesranked.com/en/company/monte-rosa-therapeutics/cash-on-handBibTeX
@misc{companiesranked-en-company-monte-rosa-therapeutics-cash-on-hand-2026,
author = {{CompaniesRanked}},
title = {{Monte Rosa Therapeutics cash}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/monte-rosa-therapeutics/cash-on-hand}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-Q · 0001193125-26-336711 · August 6, 2026
{{cite web |title=Monte Rosa Therapeutics cash — 10-Q (0001193125-26-336711) |url=https://www.sec.gov/Archives/edgar/data/1826457/000119312526336711/glue-20260630.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-08-06}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.